Tina Neogi and Greg Zwisler from PATH on Noncommunicable Diseases
Noncommunicable diseases (NCDs) represent a major and increasing global issue. It is estimated that more 36 million deaths are due to noncommunicable diseases, with more than 80% of these deaths occurring in low or middle-income countries. There are four major types of noncommunicable diseases, including cardiovascular disease, diabetes, cancer, and respiratory disease. As diabetes is a risk factor for cardiovascular disease and a cause of morbidity and mortality in it of itself, preventing diabetes and its complications is an essential component of the NCD response. Between 2012 and 2030, the number of people living with diabetes globally will increase from 371 to 552 million. PATH is invested in the NCD response, with experience of advancing technology and strengthening systems. This talk will explore the current PATH projects related to diabetes, including exploring innovative solutions in diabetes screening and management in Cambodia, bi-directional screening for tuberculosis and diabetes in Mexico, a novel diabetes and cardiovascular screening method in India, and an initial technical development of novel diagnostic test for gestational diabetes. Tina Neogi, MD, MS is an NRSA Primary Care Research Fellow in the Department of Family Medicine at the University of Washington and the Noncommunicable Disease Fellow at PATH. Her research interests are around using resource and context appropriate information and point of care technologies to improve patient empowerment, with a particular focus on underserved populations and resource-constrained settings. Greg Zwisler is a Business Officer at PATH. He is a core member of several product development teams, serving as a business generalist responsible for commercialization and market-development activities. Greg currently works on initiatives to enhance the category of oral rehydration solutions and to develop appropriate diagnostics and other technologies for use with diabetes and other non-communicable diseases (NCDs). His role and experience span market research, business strategy, product management, and partnering. His interests include consumer and industry insights, business case development, formation of partnership portfolios, and corporate intrapreneurism. Over the course of 10 years with PATH in positions of progressive responsibility, Greg has worked for short periods in Argentina, Bangladesh, Cambodia, China, Ethiopia, Ghana, India, Kenya, South Africa, Vietnam, Zambia, and various other markets. He holds an Executive MBA from the Foster School of Business at the University of Washington, and a BA from Rice University. What: Tina Neogi and Greg Zwisler from PATH on Noncommunicable Diseases When: Tuesday, April 16th at 12pm Where: The Allen Center, CSE 203
Hi everyone, I'm re-sending the email about today's Change talk because some people appeared to not receive it. Thanks Nicki Noncommunicable diseases (NCDs) represent a major and increasing global issue. It is estimated that more 36 million deaths are due to noncommunicable diseases, with more than 80% of these deaths occurring in low or middle-income countries. There are four major types of noncommunicable diseases, including cardiovascular disease, diabetes, cancer, and respiratory disease. As diabetes is a risk factor for cardiovascular disease and a cause of morbidity and mortality in it of itself, preventing diabetes and its complications is an essential component of the NCD response. Between 2012 and 2030, the number of people living with diabetes globally will increase from 371 to 552 million. PATH is invested in the NCD response, with experience of advancing technology and strengthening systems. This talk will explore the current PATH projects related to diabetes, including exploring innovative solutions in diabetes screening and management in Cambodia, bi-directional screening for tuberculosis and diabetes in Mexico, a novel diabetes and cardiovascular screening method in India, and an initial technical development of novel diagnostic test for gestational diabetes. Tina Neogi, MD, MS is an NRSA Primary Care Research Fellow in the Department of Family Medicine at the University of Washington and the Noncommunicable Disease Fellow at PATH. Her research interests are around using resource and context appropriate information and point of care technologies to improve patient empowerment, with a particular focus on underserved populations and resource-constrained settings. Greg Zwisler is a Business Officer at PATH. He is a core member of several product development teams, serving as a business generalist responsible for commercialization and market-development activities. Greg currently works on initiatives to enhance the category of oral rehydration solutions and to develop appropriate diagnostics and other technologies for use with diabetes and other non-communicable diseases (NCDs). His role and experience span market research, business strategy, product management, and partnering. His interests include consumer and industry insights, business case development, formation of partnership portfolios, and corporate intrapreneurism. Over the course of 10 years with PATH in positions of progressive responsibility, Greg has worked for short periods in Argentina, Bangladesh, Cambodia, China, Ethiopia, Ghana, India, Kenya, South Africa, Vietnam, Zambia, and various other markets. He holds an Executive MBA from the Foster School of Business at the University of Washington, and a BA from Rice University. What: Tina Neogi and Greg Zwisler from PATH on Noncommunicable Diseases When: Tuesday, April 16th at 12pm Where: The Allen Center, CSE 203
participants (1)
-
Nicola Dell